USAQ — what changed in the latest 10-Q
A section-by-section comparison of USAQ's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-14 vs the prior 10-Q · 2025-11-13
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +16 | −27 | ~8 | 5 |
| Controls & procedures | Text added/removed | 0 | 0 | ~2 | 1 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Not shown (absent or not faithfully extractable): Market risk (Item 3), Legal proceedings, Risk factors, Other information
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-14
During the fourth quarter of 2020 we began to sell the AllergiEnd® Products, consisting of AllergiEnd® Allergy Diagnostics and Allergen Immunotherapy treatments, to physicians. During the second quarter of 2022, we began to enter into SaaS subscription agreements to provide physicians with access to…
Results of Operations during the three months ended March 31, 2026 as compared to the three months ended March 31, 2025.
For the period ended March 31, 2026, we generated revenues of $728,685 compared to $645,419 of revenues for the period ended March 31, 2025. The increase in revenues for the period ended March 31, 2026, is attributed to the growth of the revenue associated with ISP services which more than made up f…
Cost of revenues consists of the cost of the AllergiEnd® test kits and allergen immunotherapy pharmacy prepared treatment sets, shipping costs to our customers as well as administrative services and labor expenses directly related to ISP sales and the amortization of our capitalized software.
The Company generated gross profit of $470,803 for the three months ended March 31, 2026, compared to $429,944 for the three months ended March 31, 2025, an increase of $40,859, or 9.5%. Gross margin decreased from 66.6% for the three months ended March 31, 2025 to 64.6% for the three months ended M…
Text removed vs the prior filing · source: 10-Q · 2025-11-13
Results of Operations during the three and nine months ended September 30, 2025 as compared to the three and nine months ended September 30, 2024
During the fourth quarter of 2020 we began to sell the AllergiEnd® Products, consisting of AllergiEnd® Allergy Diagnostics and Allergen Immunotherapy treatments, to physicians. During the second quarter of 2022, we began to enter into SaaS subscription agreements to provide physicians with access to…
For the three months ended September 30, 2025, we generated revenues of $737,066 compared to $544,285 of revenues for the three months ended September 30, 2024 which was driven by a 122% increase in our ISP revenues during the period.
For the nine months ended September 30, 2025, we generated revenues of $1,987,931 compared to $1,505,945 of revenues for the nine months ended September 30, 2024. The increase in revenues in the first nine months of 2025 were attributed to a 74.9% increase in revenues generated from ISP services to …
Cost of revenues consists of the cost of AllergiEnd® test kits and allergen immunotherapy pharmacy prepared treatment sets, shipping costs to our customers as well as administrative services and labor expenses directly related to ISP sales and the amortization of our capitalized software.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice